ESPE Abstracts (2014) 82 P-D-2-1-421

Growth Hormone

The Effects of Delaying Puberty with GnRH Agonists in Patients with Idiopathic GH Deficiency

David B Dunger a, Anders Lindberge, Helmut G Dörrc, Cecilia Camacho-Hübnerd & Mitchell E Geffnerb


aUniversity of Cambridge, Cambridge, UK; bThe Saban Research Institute of Children’s Hospital, Los Angeles, USA; cPediatric Endocrinology Division, Children’s Hospital, University of Erlangen, Erlangen, Germany; dPfizer Inc., Endocrine Care, New York, New York, USA; ePfizer Inc., Endocrine Care, Sollentuna, Sweden

Background: Treating central precocious puberty with GnRH agonist (GnRHa) to increase height gain is well-established. Although not recommended, GnRHa have also been used in patients with IGHD at onset of puberty yet there are few data on its efficacy.

Objective and hypotheses: Growth prediction models derived from KIGS (Pfizer International Growth Database) may provide an opportunity to estimate additional height gain produced by pubertal blockade.

Method: Growth data from all idiopathic GH deficiency (IGHD) patients in KIGS treated with GH and GnRHa (with start and end dates) were analyzed. From total pubertal growth (TPG) prediction models, we know the estimates for the effect of age at start of puberty, boys=−3.97 cm/year and girls=−3.68 cm/year (1). Therefore, we can estimate the effect of GnRHa by adjusting the model effect accordingly. By replacing the model effect with the actual cm in height, while on GnRHa, an estimated height gain can be calculated.

Results: All results are summarized in the Tabl: Pubertal growth in a cohort of IGHD patients treated with GH and GnRHa.

Table 1.
Boysa (n=84)Girlsa (n=113)
Start of GH
Age (years)9.79.5
Age at start of puberty11.410.3
(girls B2, boys testicular volume >3 ml)
Start of GnRHa
Age (years)12.311.2
End of GnRHa
Delta Ht (cm)9.39.3
Delta Ht (cm) adjusted per KIGS model2.73.0
Estimated cm/year1.82.2
Duration of GnRHa (years)1.61.7
aAll are median values.

Conclusion: With addition of GnRHa to treat relatively early puberty in GH-treated children with IGHD, the estimated additional median gain in adult height is 2 cm/year on GnRHa (boys=1.8 cm/year and girls=2.2 cm/year). Our data show that this therapeutic concept may not achieve the expected benefit in height according to the TPG model.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.